EW - Edwards Lifesciences Non-GAAP EPS of $0.63 misses by $0.01 revenue of $1.37B misses by $30M

• Edwards Lifesciences press release ( NYSE: EW ): Q2 Non-GAAP EPS of $0.63 misses by $0.01 .
• Revenue of $1.37B (-0.7% Y/Y) misses by $30M .
• Shares -7% .
• For total Edwards, the company now expects full year 2022 sales of $5.35 to $5.55 billion. ($5.71B CONSENSUS)  For TAVR, $3.5 to $3.7 billion; for TMTT, $110 to $140 million; for Surgical Structural Heart, $870 to $950 million; and for Critical Care, $820 to $900 million.  The company now expects full year adjusted EPS guidance at the bottom end of its original guidance range of $2.50 to $2.65, representing double-digit growth over 2021. ($2.56 consensus)
• For the third quarter of 2022, the company projects total sales to be between $1.30 and $1.37 billion, ($1.44B consensus) and adjusted EPS of $0.58 to $0.66. ($0.65 consensus)

For further details see: